Spruce Street Capital »

Inhibikase Therapeutics shares owned by Spruce Street Capital

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by Spruce Street Capital from 13F filings

Historical chart of Spruce Street Capital investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by Spruce Street Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $7.3M 3.6M 2.03

More positions owned by Spruce Street Capital

Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA)
Relay Therapeutics (RLAY)
Lb Pharmaceuticals Com Shs (LBRX)
Relmada Therapeutics (RLMD)
Alto Neuroscience Com Shs (ANRO)
Dianthus Therapeutics (DNTH)
Alkermes SHS (ALKS)
Savara (SVRA)
Vaxcyte (PCVX)
Enliven Therapeutics (ELVN)
Enanta Pharmaceuticals (ENTA)
Perspective Therapeutics Com New (CATX)
Inflarx Nv (IFRX)
Surrozen Com New (SRZN)
Alumis (ALMS)

View all positions for Spruce Street Capital

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
Trails Edge Capital Partners
ADAR1 Capital Management
BlackRock
Blackstone Group
Siren
Commodore Capital
Vanguard Capital Management
Saturn V Capital Management
Kalehua Capital Management
Spruce Street Capital
Squadron Capital Management
Millennium Management

View all funds holding Inhibikase Therapeutics